PierianDx is a leading clinical genomics informatics company that empowers progressive health institutions and diagnostic laboratories to build world-class precision medicine programs.

PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide.

PierianDx was founded in 2014 by Rakesh Nagarajan. The company is headquartered in Saint Louis, Missouri.


PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum.


PierianDx partners directly with providers, laboratories, and medical centers of all sizes to build advanced NGS testing capabilities on site using its assay-agnostic, advanced interpretation technology and enabling services.


PierianDx is backed by OrbiMed, ATW Partners, SJF Ventures, Health Catalyst Capital, RTI International, Inova Health Systems, and others. The company raised $47.5M in a growth capital financing on Nov 02, 2021. This brings PierianDx's total funding to $94.5M to date.



  • Year founded: 2014
  • Funding Info: $94.5M over 6 Rounds (Latest Funding Type: Private Equity)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Saint Louis
  • State: Missouri
  • Country: United States
Related businesses